PHAT — Phathom Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1783183 ·
Last close
$8.75
Market Cap
$707.88M
52W High
$13.39
52W Low
$8.66
ADV30
1,368,387
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 58,301,000 | 46,305,000 | -15,477,000 | -30,369,000 | 305,120,000 | 180,904,000 | 642,075,000 |
| Dec 2025 | 57,584,000 | 49,936,000 | -5,928,000 | -21,148,000 | 259,149,000 | 129,972,000 | 697,318,000 |
| Sep 2025 | 49,504,000 | 43,314,000 | -15,271,000 | -29,973,000 | 240,289,000 | 135,156,000 | 662,823,000 |
| Jun 2025 | 39,503,000 | 34,465,000 | -59,924,000 | -75,810,000 | 250,220,000 | 149,569,000 | 656,054,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-97,492,000
Investing CF
$-272,000
Financing CF
$66,352,000
CapEx
$-272,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.12
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,514,627,000
Inventory
$6,508,000
Receivables
$80,724,000
ST Investments
—
EBIT TTM
$-91,458,000
Pretax Income TTM
$-157,300,000
Interest Exp TTM
$65,842,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$239,662,000
EBITDA
$-40,134,000
Free Cash Flow
$-31,061,124
Enterprise Value
$1,100,081,408
Total Cash
$182,478,000
Total Debt
$552,024,000
Shares Out
80,900,934
Trailing EPS
$-1.25
Book Value
$-6.13
ROE
—
ROA
-8.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 175,110,000 | -159,986,000 | -221,247,000 | 259,149,000 | 697,318,000 | — | -166,775,000 |
| Dec 2024 | 55,252,000 | -277,467,000 | -334,326,000 | 378,318,000 | 631,898,000 | — | -266,770,000 |
| Dec 2023 | 682,000 | -167,312,000 | -201,592,000 | 413,842,000 | 486,601,000 | — | -137,580,000 |
| Dec 2022 | 0 | -172,440,000 | -197,723,000 | 164,810,000 | 239,624,000 | — | -146,530,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.36
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XOMA | XOMA Royalty Corp | $710.16M | $40.17 | — |
| PHAR | Pharming Group N.V. | $713.44M | $10.08 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $718.83M | $73.26 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $696.31M | $4.23 | — |
| MNPR | Monopar Therapeutics | $725.84M | $108.35 | — |
News headlines (Yahoo Finance, 1h cache)
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?
2026-07-30 22:09 · Yahoo
Phathom Pharmaceuticals Q2 Earnings Call Highlights
2026-07-30 19:04 · Yahoo
Phathom Pharmaceuticals Inc (PHAT) (Q2 2026) Earnings Call Highlights: First Positive Operating ...
2026-07-30 19:01 · Yahoo
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
2026-07-30 14:30 · Yahoo
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-30 10:59 · Yahoo
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
2026-07-20 12:00 · Yahoo
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
2026-06-23 11:59 · Yahoo
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-22 12:00 · Yahoo
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
2026-05-20 12:00 · Yahoo
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline
2026-05-05 10:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.